Victoria Taylor

Victoria is a Principal at Medicxi. Prior to joining Medicxi, Victoria worked at the Foundation Institute for 21st Century Medicine (C21Med), focusing on early-stage company creation and operations. Here she co-founded a number of companies that received Medicxi investment including Imhotex, Perfect Balance and Pandeia Therapeutics (sold to an undisclosed party).

Victoria currently serves on the boards of portfolio companies Neurommune and Tactix Bio and has supported on a number of Medicxi investments including RAPT Therapeutics (acquired by GSK) and MiroBio (acquired by Gilead Sciences).

Victoria graduated with an MBiochem in Molecular and Cellular Biochemistry from the University of Oxford.